Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Coherus prices biosimilar to Amgen’s Neulasta at 33 percent discount

Coherus BioSciences Inc. will price the company’s biosimilar to Amgen Inc.’s infection-fighting treatment Neulasta at a 33 percent discount.

Read More »

Amgen cuts price of cholesterol drug Repatha

Amgen Inc., looking to boost use of the U.S. biotechnology company’s potent cholesterol drug Repatha, cut the medication’s U.S. list price by 60 percent to $5,850.

Read More »

Trump to sign anti-opioid abuse package

Medical treatment would be more widely available to opioid abusers under a rare bipartisan measure aimed at tackling the U.S. addiction crisis expected to be signed into law by President Trump.

Read More »

FDA Proposes Steps to Standardize Generic Drugs Globally

U.S. Food and Drug Administration Commissioner Scott Gottlieb announced that the regulatory agency is relaunching the Drug Competition Action Plan in 2019 with some additional initiatives.

Read More »

FDA snubs Novartis bid to repurpose inflammation drug for heart attacks

The U.S. Food and Drug Administration rejected Novartis’ bid to repurpose canakinumab, a drug already approved for rare inflammatory diseases, for use in a group of heart attack survivors.

Read More »

Cost of blood pressure drug surges in U.S. after recall

Prices for two dosages of the blood pressure drug valsartan rose more than any other drug in the United States during September 2018, following a recall of much of the drug’s supply.

Read More »

U.S. to propose TV drug ads must include list prices

The U.S. government, in an effort to increase pressure on drugmakers to lower costs for U.S. consumers, will propose requiring companies to include the price of Rx medicines in TV ads.

Read More »

Trump Signs FTC Law That Allows for Biosimilar Scrutiny

President Donald Trump signed a bill into law that requires pharmaceutical companies to provide details of biosimilar deals to the Federal Trade Commission for antitrust scrutiny.

Read More »

Mental health crisis could cost the world $16 trillion by 2030

Mental health disorders are on the rise in every country in the world and could cost the global economy up to $16 trillion between 2010 and 2030 if a collective failure to respond is not addressed, according to an expert report.

Read More »

Merck’s Frazier Joins Growing List of Pharma CEOs Attacking Drug Rebates

Merck & Co. CEO Kenneth Frazier, speaking with the Economic Club of New York, joined a growing list of pharmaceutical chiefs in criticizing the role of middlemen in rising drug prices.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom